REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RVNC	
Last Trade:	33.81
Trade Time:	10:02 AM ET Dec 14, 2017
Change:	-0.29 (-0.843%)
Day Range	33.27 - 34.40
52-Week Range	16.40 - 37.20
Volume	83,064

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comp... (more)

Stock Performance



Press Releases [View all]

Dec 11, 2017
Revance Announces Closing of Public Offering of Common Stock

Dec 7, 2017
Revance Announces Pricing of Public Offering of Common Stock

Dec 5, 2017
Revance Announces Proposed Public Offering of Common Stock

Dec 5, 2017
Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines

Nov 29, 2017
Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia

Financials [View all]

Third Quarter Financial Results

Feb 28, 2017
Annual Report (10-K)

Mar 24, 2017
Proxy Statement (DEF 14A)

Nov 3, 2017
Quarterly Report (10-Q)

Aug 4, 2017
Quarterly Report (10-Q)

May 9, 2017
Quarterly Report (10-Q)